Indoco Remedies Blood-thinner Apixaban gets USFDA green flag
It is used for patients with health problems caused by a blood clot.
Mumbai: Drugmaker Indoco Remedies today announced that the company has received US Food and Drug Administration (USFDA) approval for abbreviated new drug application(ANDA) for Apixaban Tablets 2.5mg & 5mg.
The products are therapeutically equivalent to the Reference Listed Drug 'Eliquis' of Bristol-Myers Squibb (BMS).
Apixaban is an anticoagulant, or blood thinner. It is used for patients with health problems caused by a blood clot.
The US market size of Apixaban Tablets is USD 11,037 million as per IMS MAT June'20 data.
Commenting on this development, Ms. Aditi Kare Panandikar, Managing Director - Indoco Remedies Ltd. said, "The receipt of approval from the US health regulator for the generic version of Apixaban Tablets is encouraging."
Read also: Indoco Remedies gets USFDA nod to Olanzapine Tablets to treat schizophrenia, bipolar disorder
Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries.
Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets.
The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility.
Read also: Granules India Dexmethylphenidate HCl ER capsules get USFDA approval to treat ADHD
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.